RCS - Oxford BioDynamics - Pfizer study on EpiSwitch biomarkers

Oxford BiodynamicsAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250715:nRSO0151Ra&default-theme=true

RNS Number : 0151R  Oxford BioDynamics PLC  15 July 2025

15 July 2025

Oxford BioDynamics plc

("Oxford BioDynamics" or the "Company")

 

Pfizer publishes on successful use of EpiSwitch biomarkers evaluating tumour
status and treatment outcomes from the JAVELIN Bladder 100 Trial

·      Results strongly support the use of EpiSwitch blood-based
biomarkers as an effective liquid biopsy method to evaluate and monitor the
state of tissues and tumors in cancer patients

 

Oxford, UK - 15 July 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision
clinical diagnostics company bringing specific and sensitive tests to the
practice of medicine based on its EpiSwitch® 3D genomics platform, is pleased
to note the publication of data from Pfizer on the successful use of EpiSwitch
blood-based biomarkers in the evaluation of tumour status and treatment
outcomes of 496 patients from the JAVELIN Bladder 100 Trial in the journal
Cancers( 1 ).  The trial demonstrated a significant survival benefit with
(immune checkpoint inhibitor) avelumab maintenance plus best supportive care
(BSC) versus BSC alone. EpiSwitch blood-based biomarkers were evaluated on
their association with tumour profiles and their immunophenotype, related to
high and low immunogenic response.

 

In addition to Pfizer's Computional Biology, Translational Pathology and
Precision Medicine Product teams, the study has been conducted in
collaboration with St. Bartholomew's Hospital, London, UK; Princess Margaret
Cancer Centre, Toronto, Canada; Dana-Farber Cancer Institute, Harvard Medical
School, Boston, MA, USA; Englander Institute for Precision Medicine, Weill
Cornell Medicine, Meyer Cancer Center, New York, NY, USA; Fred Hutchinson
Cancer Center, Seattle, WA, USA; and Data4Cure, Inc., Waltham, MA, USA.

 

The data demonstrates that EpiSwitch biomarkers in blood samples strongly
correlate with the immune profiles of patient tumours. The researchers
conclude that EpiSwitch blood testing can effectively determine whether a
tumour has high or low immune activity, which is an important factor in making
informed cancer treatment decisions. The EpiSwitch technology provides
accurate insights into the body's immune response to the cancer in a less
invasive manner than traditional tissue biopsies. The ability to utilise this
technology to identify which patients are most likely to benefit from specific
treatment options represents a significant advancement in patient care. These
results support the growing evidence that EpiSwitch technology, already
utilised in prostate cancer testing, has the potential to
revolutionise cancer detection and monitoring across various types of cancer.
These advancements position Oxford BioDynamics to expand its role in the
rapidly growing cancer diagnostics market, highlighting the company's
potential for substantial growth and impact in precision medicine.

Dr. Alexandre Akoulitchev, Chief Scientific Officer of OBD said:

"The results from the published Pfizer study are a powerful endorsement for
our blood-based biomarker EpiSwitch technology. Our systemic epigenetic
readouts showed consistent insights into JAVELIN Bladder 100 patient profiles,
normally obtained through biopsies and complex gene expression analysis. This
is a typical example of benefits that EpiSwitch technology has been offering
our  pharmaceutical partners.

EpiSwitch biomarker products have already proven their quality and have been
translated into clinical practice  2 . Our EpiSwitch PSE test for early
prostate cancer detection is  demonstrating impressive real-world clinical
utility, with rapidly growing adoption across both the US and UK market  3,4 .
With its remarkable 94% accuracy compared to standard PSA testing's 55%, our
technology is transforming cancer detection capabilities.

The Pfizer study adds to the extensive evidence of EpiSwitch biomarkers
quality, efficacy, and their full potential -all powered by our innovative
EpiSwitch platform and AI-powered 3D Genomics KnowledgeBase  2 ."

References:

 1  Powles, T.; Sridhar, S.S.; Bellmunt, J.; Sternberg, C.N.; Grivas, P.;
Hunter, E.; Salter, M.; Powell, R.; Dring, A.; Green, J.; et al.
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients
with Urothelial Carcinoma from JAVELIN Bladder 100. Cancers 2025, 17, 2332.
https://doi.org/10.3390/cancers17142332
(https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.3390%2Fcancers17142332&data=05%7C02%7CFergus.Young%40camarco.co.uk%7C2570f3019e794eb776c108ddc2f13e7f%7C77a5f6209d7747dba0cd64c70948d532%7C1%7C0%7C638881063732975231%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=A5CbXJmVJzUh%2Bq5rXGgDiz6RqI39xudwqkWYGfGWLco%3D&reserved=0)

 

 2         Mellor, J.; Hunter, E.; Akoulitchev, A. Paradigm
Lost. Cancers 2025, 17, 2187. https://doi.org/10.3390/cancers17132187

 3         Pchejetski, D.; Hunter, E.; Dezfouli, M.; Salter, M.;
Powell, R.; Green, J.; Naithani, T.; Koutsothanasi, C.; Alshaker, H.;
Jaipuria, J.; et al. Circulating Chromosome Conformation Signatures
Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for
Prostate Cancer Detection. Cancers 2023, 15, 821.
https://doi.org/10.3390/cancers15030821
(https://doi.org/10.3390/cancers15030821)

 4         Berghausen, J.; Abdo, J.; Mathis, R.; Hunter, E.;
Akoulitchev, A.; Pohlman, G.D. EpiSwitch PSE Blood Test Reduces Unnecessary
Prostate Biopsies: A Real-World Clinical Utility Study. Cancers 2025, 17,
2193. https://doi.org/10.3390/cancers17132193
(https://doi.org/10.3390/cancers17132193)

 

-Ends-

For further information please contact:

 Oxford BioDynamics Plc                       +44 (0)1865 518910

 Iain Ross, Executive Chairman

 Paul Stockdale, CFO

 Camarco - Financial PR

 Marc Cohen / Tilly Butcher / Fergus Young    +44 (0)20 3757 4980

                                              OBDFinancial@camarco.co.uk

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(http://www.oxfordbiodynamics.com/) ,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFEADLISLIE